CCR5 and metabolic dysfunction-associated steatohepatitis: Anti-CCR2/CCR5 drugs (NCT02217475; NCT03028740; NCT03059446; NCT02330549) for liver fibrosis and non-alcoholic steatohepatitis are in phase 2 or 3 clinical trials for antifibrotic therapy (16).